Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Moderna's Stéphane Bancel is stepping down from his role as chief commercial officer, a significant shift for the company as it approaches the rollout of several new vaccines. Source: Pixabay.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

(Reuters) - Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new ...